To date, many studies on BCL-XL inhibitors have focused on solid tumors (such as breast cancer, non-SCLC, ovarian cancer, colorectal cancer, and multiple myeloma) because solid tumors rely on BCL-XL for their survival. The gene discussed is BCL2L1; the disease is ovarian carcinoma.